David Rubin to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications David Rubin has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.314
-
Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel Disease. Gastroenterology. 2022 01; 162(1):17-21.
Score: 0.177
-
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025 Jan 08; 12(1).
Score: 0.056
-
Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European Gastroenterol J. 2023 10; 11(8):797-806.
Score: 0.051
-
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017 02; 15(2):229-239.e5.
Score: 0.031